As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, ...

Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Analyst Terence Flynn from Morgan Stanley reiterated a Sell rating on Bristol-Myers Squibb (BMY – Research Report) and decreased the ...

New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several ...

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $113.5 ...